Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

NCT: NCT07058883 · RECRUITING

NCT IDNCT07058883
StatusRECRUITING
Start Date2026-03-13
Completion2027-03
SponsorNordberg Medical AB (INDUSTRY)
First posted
Last updated

Brief Summary

This study aims to evaluate the effectiveness and safety of Juläine, an injectable medical device made of polylactic acid, for treating facial acne scars. Participants with atrophic acne scars will be randomly assigned to receive either Juläine or a placebo (saline). The treatment will consist of three injection sessions over two months, followed by a 12-month observation period. The study will measure changes in scar severity and skin quality over time using clinical assessments and imaging tools. The study is being conducted at multiple dermatology clinics in Poland and is approved by a local ethics committee.

Frequently Asked Questions

What is Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars?

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars is a clinical trial registered under NCT07058883. Current status: RECRUITING.

What is the status of NCT07058883?

The current status of NCT07058883 (Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars) is: RECRUITING.

When did Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars start?

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars started on 2026-03-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑